Showing results (11-20 of 61) with videos related to
Sort By:
Pageof 7
Clinical Pharmacology and Therapeutics|September 15, 2001
Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedicationsJ M Kovarik, C H Hsu, L McMahon, et al.Pediatric Nephrology (Berlin, Germany)|October 25, 2003
Cyclosporine absorption profiles in pediatric kidney and liver transplant patientsJ M Kovarik, Peter F Hoyer, Robert Ettenger, et al.Journal of Clinical Pharmacology|June 1, 1993
Pharmacokinetics of cyclosporine and steady-state aspirin during coadministrationJ M Kovarik, E A Mueller, M Gaber, et al.Pharmacotherapy|November 1, 1993
Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulationJ M Kovarik, E A Mueller, A Johnston, et al.Clinical Pharmacy|May 1, 1985
Evaluation of the vancomycin-clearance:creatinine-clearance relationship for predicting vancomycin dosageG R Matzke, J M Kovarik, M J Rybak, et al.Pediatric Transplantation|May 19, 2011
Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplantsR Ettenger, R Schmouder, J M Kovarik, et al.Antimicrobial Agents and Chemotherapy|December 1, 1995
Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolitesJ M Kovarik, E A Mueller, H Zehender, et al.Journal of Clinical Pharmacology|April 1, 1997
Cyclosporine and nonsteroidal antiinflammatory drugs: exploring potential drug interactions and their implications for the treatment of rheumatoid arthritisJ M Kovarik, E A Mueller, C Gerbeau, et al.Transplantation|February 24, 2001
Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipientsG A Levy, D Grant, K Paradis, et al.Journal of Pharmaceutical Sciences|March 1, 1994
Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulationJ M Kovarik, E A Mueller, J B van Bree, et al.Pageof 7